Biobetter Versions of Recombinant Human IFN-α2b for the Treatment of Viral Infections
- Autores
- Mufarrege, Eduardo Federico; Peña, Lucía Carolina; Echeverrigaray, Marina
- Año de publicación
- 2023
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the infectious agent causing COVID-19 disease, whose pandemic has had far-reaching consequences on the global population. Since the detection of the first cases in late 2019, much has been learned about the mechanism of action of SARS-CoV-2 and the associated immune response to eradicate the infection. Recently, a clear correlation between disease severity and abnormal type I IFN response in patients has been established. Individuals with immune responses characterized by high concentrations of IFN-a2b and low blood levels of IL-6, TNF-alpha, and IL-1Ra were much less affected than those patients who exhibited an opposite scenario. Interestingly, recombinant human IFN-a2b (rhIFN-a2b) could mitigate the severity of symptoms, if given in the early stages of the disease, before reaching the inflammatory shock (cytokine storm) that characterizes the most severe cases. However, there are adverse effects associated with rhIFN-a2b-based therapy. Among them, the emergence of unwanted immune responses against the biologic can, in some cases, compromise the treatment’s safety and efficacy. In addition, rhIFN-a2b is a small cytokine, which results in rapid clearance from the bloodstream. This quick plasma clearance poses the need for frequent high doses to achieve the desired effect, which may, in turn, exacerbate unwanted effects associated with therapy.In this article we will address the most relevant strategies for the development of biobetters versions of rhIFN-a2b, as promising candidates for the treatment of COVID-19 and other human viral diseases.
Fil: Mufarrege, Eduardo Federico. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Cultivos Celulares; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Santa Fe; Argentina
Fil: Peña, Lucía Carolina. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Cultivos Celulares; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Santa Fe; Argentina
Fil: Echeverrigaray, Marina. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Cultivos Celulares; Argentina - Materia
-
SARS-COV-2
COVID-19
IFN-A2B
IMMUNOGENICITY
PEGYLATION
GLYCOSYLATION
BIOBETTER - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/239015
Ver los metadatos del registro completo
id |
CONICETDig_fde37505ba32697c9d74cf5db98fe835 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/239015 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Biobetter Versions of Recombinant Human IFN-α2b for the Treatment of Viral InfectionsMufarrege, Eduardo FedericoPeña, Lucía CarolinaEcheverrigaray, MarinaSARS-COV-2COVID-19IFN-A2BIMMUNOGENICITYPEGYLATIONGLYCOSYLATIONBIOBETTERhttps://purl.org/becyt/ford/3.4https://purl.org/becyt/ford/3Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the infectious agent causing COVID-19 disease, whose pandemic has had far-reaching consequences on the global population. Since the detection of the first cases in late 2019, much has been learned about the mechanism of action of SARS-CoV-2 and the associated immune response to eradicate the infection. Recently, a clear correlation between disease severity and abnormal type I IFN response in patients has been established. Individuals with immune responses characterized by high concentrations of IFN-a2b and low blood levels of IL-6, TNF-alpha, and IL-1Ra were much less affected than those patients who exhibited an opposite scenario. Interestingly, recombinant human IFN-a2b (rhIFN-a2b) could mitigate the severity of symptoms, if given in the early stages of the disease, before reaching the inflammatory shock (cytokine storm) that characterizes the most severe cases. However, there are adverse effects associated with rhIFN-a2b-based therapy. Among them, the emergence of unwanted immune responses against the biologic can, in some cases, compromise the treatment’s safety and efficacy. In addition, rhIFN-a2b is a small cytokine, which results in rapid clearance from the bloodstream. This quick plasma clearance poses the need for frequent high doses to achieve the desired effect, which may, in turn, exacerbate unwanted effects associated with therapy.In this article we will address the most relevant strategies for the development of biobetters versions of rhIFN-a2b, as promising candidates for the treatment of COVID-19 and other human viral diseases.Fil: Mufarrege, Eduardo Federico. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Cultivos Celulares; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Santa Fe; ArgentinaFil: Peña, Lucía Carolina. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Cultivos Celulares; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Santa Fe; ArgentinaFil: Echeverrigaray, Marina. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Cultivos Celulares; ArgentinaGavin Publishers2023-10info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/239015Mufarrege, Eduardo Federico; Peña, Lucía Carolina; Echeverrigaray, Marina ; Biobetter Versions of Recombinant Human IFN-α2b for the Treatment of Viral Infections; Gavin Publishers; Infectious Diseases Diagnosis & Treatment; 7; 3; 10-2023; 1-22577-1515CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.29011/2577-1515.100236info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:14:17Zoai:ri.conicet.gov.ar:11336/239015instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:14:17.522CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Biobetter Versions of Recombinant Human IFN-α2b for the Treatment of Viral Infections |
title |
Biobetter Versions of Recombinant Human IFN-α2b for the Treatment of Viral Infections |
spellingShingle |
Biobetter Versions of Recombinant Human IFN-α2b for the Treatment of Viral Infections Mufarrege, Eduardo Federico SARS-COV-2 COVID-19 IFN-A2B IMMUNOGENICITY PEGYLATION GLYCOSYLATION BIOBETTER |
title_short |
Biobetter Versions of Recombinant Human IFN-α2b for the Treatment of Viral Infections |
title_full |
Biobetter Versions of Recombinant Human IFN-α2b for the Treatment of Viral Infections |
title_fullStr |
Biobetter Versions of Recombinant Human IFN-α2b for the Treatment of Viral Infections |
title_full_unstemmed |
Biobetter Versions of Recombinant Human IFN-α2b for the Treatment of Viral Infections |
title_sort |
Biobetter Versions of Recombinant Human IFN-α2b for the Treatment of Viral Infections |
dc.creator.none.fl_str_mv |
Mufarrege, Eduardo Federico Peña, Lucía Carolina Echeverrigaray, Marina |
author |
Mufarrege, Eduardo Federico |
author_facet |
Mufarrege, Eduardo Federico Peña, Lucía Carolina Echeverrigaray, Marina |
author_role |
author |
author2 |
Peña, Lucía Carolina Echeverrigaray, Marina |
author2_role |
author author |
dc.subject.none.fl_str_mv |
SARS-COV-2 COVID-19 IFN-A2B IMMUNOGENICITY PEGYLATION GLYCOSYLATION BIOBETTER |
topic |
SARS-COV-2 COVID-19 IFN-A2B IMMUNOGENICITY PEGYLATION GLYCOSYLATION BIOBETTER |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.4 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the infectious agent causing COVID-19 disease, whose pandemic has had far-reaching consequences on the global population. Since the detection of the first cases in late 2019, much has been learned about the mechanism of action of SARS-CoV-2 and the associated immune response to eradicate the infection. Recently, a clear correlation between disease severity and abnormal type I IFN response in patients has been established. Individuals with immune responses characterized by high concentrations of IFN-a2b and low blood levels of IL-6, TNF-alpha, and IL-1Ra were much less affected than those patients who exhibited an opposite scenario. Interestingly, recombinant human IFN-a2b (rhIFN-a2b) could mitigate the severity of symptoms, if given in the early stages of the disease, before reaching the inflammatory shock (cytokine storm) that characterizes the most severe cases. However, there are adverse effects associated with rhIFN-a2b-based therapy. Among them, the emergence of unwanted immune responses against the biologic can, in some cases, compromise the treatment’s safety and efficacy. In addition, rhIFN-a2b is a small cytokine, which results in rapid clearance from the bloodstream. This quick plasma clearance poses the need for frequent high doses to achieve the desired effect, which may, in turn, exacerbate unwanted effects associated with therapy.In this article we will address the most relevant strategies for the development of biobetters versions of rhIFN-a2b, as promising candidates for the treatment of COVID-19 and other human viral diseases. Fil: Mufarrege, Eduardo Federico. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Cultivos Celulares; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Santa Fe; Argentina Fil: Peña, Lucía Carolina. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Cultivos Celulares; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Santa Fe; Argentina Fil: Echeverrigaray, Marina. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Cultivos Celulares; Argentina |
description |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the infectious agent causing COVID-19 disease, whose pandemic has had far-reaching consequences on the global population. Since the detection of the first cases in late 2019, much has been learned about the mechanism of action of SARS-CoV-2 and the associated immune response to eradicate the infection. Recently, a clear correlation between disease severity and abnormal type I IFN response in patients has been established. Individuals with immune responses characterized by high concentrations of IFN-a2b and low blood levels of IL-6, TNF-alpha, and IL-1Ra were much less affected than those patients who exhibited an opposite scenario. Interestingly, recombinant human IFN-a2b (rhIFN-a2b) could mitigate the severity of symptoms, if given in the early stages of the disease, before reaching the inflammatory shock (cytokine storm) that characterizes the most severe cases. However, there are adverse effects associated with rhIFN-a2b-based therapy. Among them, the emergence of unwanted immune responses against the biologic can, in some cases, compromise the treatment’s safety and efficacy. In addition, rhIFN-a2b is a small cytokine, which results in rapid clearance from the bloodstream. This quick plasma clearance poses the need for frequent high doses to achieve the desired effect, which may, in turn, exacerbate unwanted effects associated with therapy.In this article we will address the most relevant strategies for the development of biobetters versions of rhIFN-a2b, as promising candidates for the treatment of COVID-19 and other human viral diseases. |
publishDate |
2023 |
dc.date.none.fl_str_mv |
2023-10 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/239015 Mufarrege, Eduardo Federico; Peña, Lucía Carolina; Echeverrigaray, Marina ; Biobetter Versions of Recombinant Human IFN-α2b for the Treatment of Viral Infections; Gavin Publishers; Infectious Diseases Diagnosis & Treatment; 7; 3; 10-2023; 1-2 2577-1515 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/239015 |
identifier_str_mv |
Mufarrege, Eduardo Federico; Peña, Lucía Carolina; Echeverrigaray, Marina ; Biobetter Versions of Recombinant Human IFN-α2b for the Treatment of Viral Infections; Gavin Publishers; Infectious Diseases Diagnosis & Treatment; 7; 3; 10-2023; 1-2 2577-1515 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/doi/10.29011/2577-1515.100236 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Gavin Publishers |
publisher.none.fl_str_mv |
Gavin Publishers |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1844614069002174464 |
score |
13.070432 |